• Explore /
  • Poster
  • / Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.

Abstract Poster

Authors

null

Tomohiro Nishina

Shikoku Cancer Center, Matsuyama, Japan

Tomohiro Nishina , Kohei Shitara , Satoru Iwasa , Shuichi Hironaka , Kei Muro , Taito Esaki , Taroh Satoh , Kensei Yamaguchi , Nozomu Machida , Anja von Heydebreck , Morihiro Watanabe , Toshihiko Doi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01943461

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 168)

DOI

10.1200/jco.2016.34.4_suppl.168

Abstract #

168

Poster Bd #

N16

Abstract Disclosures

Similar Posters

First Author: Hyun Cheol Chung

First Author: Thorsten Oliver Goetze

First Author: Thorsten Oliver Goetze

First Author: Junho Kang